Summary of Evan Hughes's The Hard Sell

Everest Media

Description

Please note: This is a companion version & not the original book.
Sample Book Insights:
#1 Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.
#2 Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.
#3 Kapoor’s company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.
#4 After the acquisition, Lyphomed’s value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.

Sujets

• True Crime
• Organized Crime

Informations

• Publié par: Everest Media LLC
• Date de parution: 25 juillet 2022
• Nombre de lectures: 0
• EAN13: 9798822547421
• Langue: English
• Poids de l'ouvrage: 1 Mo

Extrait

Insights on Evan Hughes's The Hard Sell
Contents Insights from Chapter 1 Insights from Chapter 2 Insights from Chapter 3 Insights from Chapter 4 Insights from Chapter 5 Insights from Chapter 6 Insights from Chapter 7 Insights from Chapter 8 Insights from Chapter 9 Insights from Chapter 10 Insights from Chapter 11 Insights from Chapter 12 Insights from Chapter 13 Insights from Chapter 14 Insights from Chapter 15 Insights from Chapter 16 Insights from Chapter 17 Insights from Chapter 18 Insights from Chapter 19 Insights from Chapter 20 Insights from Chapter 21 Insights from Chapter 22
Insights from Chapter 1

#1

Mike Babich was a wealth manager at Northern Trust, a Chicago banking institution, who was offered a job by a high-net-worth individual in the pharmaceutical business. He didn't know much about his client, but he accepted the offer.

#2

Kapoor was a pharmaceutical industry mogul who made his fortune by developing generic medications. He was the largest shareholder in at least five companies. He had made a fortune as a biotech entrepreneur.

#3

Kapoor’s company, Lypho-Med, was a powerhouse in the generic drug business. In the 1980s, government incentives favored cheaper alternatives to branded medications. Kapoor was a consistent winner, and his company grew rapidly under his ownership.

#4

After the acquisition, Lyphomed’s value and reputation were destroyed. In 1992, Fujisawa sued Kapoor, alleging that he had concealed devastating FDA problems during the sale. The buyer was accusing Kapoor of selling a lemon.

#5

After the meeting, Babich felt he had been quietly passed over for the job. A second interview was followed by another lengthy unexplained silence. When Babich finally got a job offer, it came in the form of a letter in the mail. He accepted.

#6

Babich learned that pleasing his boss could bring rewards. He was learning how to please his boss, and he was learning that it could bring rewards.
Insights from Chapter 2

#1

The company’s assets consisted of some equipment in a rented lab space in Mundelein, Illinois, not far from Kapoor’s home base in Lake Forest. They planned to win the race to market the first generic version of Marinol, a branded treatment for nausea and vomiting induced by chemotherapy, and for wasting caused by AIDS.

#2

The aim of Subsys was to help people like Kapoor’s wife, who was battling severe pain. It was a great business idea, but it had the potential to be a risky endeavor.

#3

The only distinction among the TIRF products was how exactly the fentanyl was delivered into the body. Actiq is a lozenge on a stick, while Fentora is an effervescent tablet that dissolves between the gum and the cheek.

#4

The fact that a doctor can prescribe a drug for any use naturally grows the potential market for it. With TIRF drugs, off-label uses constituted the lion’s share of the business.